8-K: cbdMD, Inc. Faces Delisting Threat After Failing to Meet NYSE American Listing Standards

cbdMD, Inc. has received a notice from the NYSE American for not meeting continued listing standards due to insufficient stockholders' equity.

Summary

• cbdMD, Inc. received a notification from the NYSE American on June 5, 2024, stating that the company is not in compliance with continued listing standards.
• The company's stockholders' equity was reported at $3.1 million as of March 31, 2024, which is below the required $4 million threshold.
• This non-compliance is due to the company reporting losses from continuing operations and/or net losses in three of its four most recent fiscal years.
• cbdMD must submit a plan by July 5, 2024, to regain compliance by December 5, 2025.
• The plan must include specific milestones, quarterly financial projections, and details of strategic initiatives.
• Failure to submit or have the plan accepted, or failure to meet the plan's requirements, could lead to delisting.
• The company's common stock and preferred stock will continue to trade on the NYSE American with a '.BC' designation indicating non-compliance.
• The company is exploring options, including a potential conversion of preferred stock and its accrued dividend of $2.7 million, to increase stockholder equity.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges and a potential delisting, which is a negative signal for investors. While the company is taking steps to address the issues, the uncertainty and risk are high.

Positives

• The company is actively preparing a plan to regain compliance with NYSE American listing standards.
• The company is exploring options to increase stockholder equity, including a potential conversion of preferred stock.
• The company has announced significant cost reductions that will be in place by August 2024.
• The company's stock will continue to trade on the NYSE American during the plan period, albeit with a non-compliance designation.

Negatives

• The company is not in compliance with NYSE American listing standards due to insufficient stockholders' equity.
• The company has reported losses in three of the last four fiscal years.
• Failure to regain compliance could lead to delisting, which could negatively impact the company's stock price and ability to raise capital.
• Delisting could trigger an event of default under the company's outstanding Senior Secured Convertible Promissory Notes.

Risks

• There is no guarantee that the company will be able to regain compliance with the NYSE American listing standards.
• Delisting could reduce the liquidity and market price of the company's stock.
• Delisting could limit the company's ability to raise equity financing.
• Delisting could trigger an event of default under the company's outstanding Senior Secured Convertible Promissory Notes.
• The company's ability to access public capital markets could be limited if delisted.

Future Outlook

The company is focused on achieving positive net income and is working on a plan to regain compliance with NYSE American listing standards by December 5, 2025. They are exploring options including a potential conversion of preferred stock and its accrued dividend to increase stockholder equity. There is no guarantee that the company will be able to regain compliance.

Management Comments

• The company is committed to undertaking a transaction or transactions in the future to achieve compliance with the NYSE Americans requirements.
• The company is focused on achieving positive net income and has already announced significant cost reductions that will be in place by August 2024.

Industry Context

The CBD industry is facing increasing competition and regulatory challenges, which may be contributing to cbdMD's financial difficulties. Other companies in the sector may also be facing similar pressures to maintain profitability and meet listing requirements.

Comparison to Industry Standards

• Many smaller companies in the CBD sector are struggling to achieve profitability and maintain listing compliance.
• Companies like Charlotte's Web and Canopy Growth have also faced challenges in maintaining profitability and meeting listing requirements, although they are generally larger and more established than cbdMD.
• The requirement for $4 million in stockholders' equity is a common benchmark for continued listing on exchanges like NYSE American, and failure to meet this standard is a significant concern.

Stakeholder Impact

• Shareholders face the risk of delisting and a potential decrease in stock value.
• Employees may be affected by cost reductions and potential restructuring.
• Customers may be concerned about the company's long-term viability.
• Suppliers and creditors may face increased risk due to the company's financial challenges.

Next Steps

• The company must submit a compliance plan to the NYSE American by July 5, 2024.
• The company will continue to work on strategic initiatives to improve its financial position.
• The company will seek shareholder approval to convert the Preferred Stock and its accrued dividend.

Key Dates

Keywords

NYSE American, delisting, compliance, stockholders' equity, listing standards, cbdMD, YCBD, preferred stock, financial performance, cost reductions